Cargando…

Treatment of acquired hemophilia A, a balancing act: results from a 27‐year Dutch cohort study

Acquired hemophilia A (AHA) is a severe auto‐immune bleeding disorder. Treatment of AHA is burdensome and optimal management is still unresolved. Therefore a retrospective nationwide multi‐center cohort study (1992‐2018) was performed to evaluate clinical presentation and treatment efficacy and safe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schep, Sarah J., van Dijk, Wobke E. M., Beckers, Erik A. M., Meijer, Karina, Coppens, Michiel, Eikenboom, Jeroen, Leebeek, Frank W. G., van Vulpen, Lize F. D., Fischer, Kathelijn F., Schutgens, Roger E. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756759/ https://www.ncbi.nlm.nih.gov/pubmed/32974947 http://dx.doi.org/10.1002/ajh.26009

Ejemplares similares

Hepatitis C virus in hemophilia: Health‐related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study
por: Isfordink, Cas J., et al.
Publicado: (2021)

Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study
por: van Balen, Erna C., et al.
Publicado: (2022)

Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study
por: Versloot, Olav, et al.
Publicado: (2021)

Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study
por: Van Der Valk, Paul, et al.
Publicado: (2022)

Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands
por: van Balen, Erna C., et al.
Publicado: (2021)

Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
por: Hassan, Shermarke, et al.
Publicado: (2021)

Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A
por: Schep, Sarah J., et al.
Publicado: (2021)

In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype
por: Verhagen, Marieke J.A., et al.
Publicado: (2023)

Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018
por: Hassan, Shermarke, et al.
Publicado: (2020)

Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
por: Goedhart, Tine M.H.J., et al.
Publicado: (2022)

Relapse of immune thrombocytopenia after COVID‐19 vaccination
por: van Dijk, Wobke E. M., et al.
Publicado: (2021)

Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A
por: ten Ham, Renske M.T., et al.
Publicado: (2022)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Generic PROMIS item banks in adults with hemophilia for patient‐reported outcome assessment: Feasibility, measurement properties, and relevance
por: Kuijlaars, Isolde A. R., et al.
Publicado: (2021)

Adherence to prophylaxis and its association with activation of self‐management and treatment satisfaction
por: Hoefnagels, Johanna Wilhelmina, et al.
Publicado: (2021)

Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study
por: van Galen, Karin P.M., et al.
Publicado: (2017)

Validation of the pedHAL(short) and HAL(short) in Dutch children and adults with haemophilia
por: Kuijlaars, Isolde A. R., et al.
Publicado: (2022)

Bleeding phenotype and diagnostic characterization of patients with congenital platelet defects
por: Blaauwgeers, Maaike W., et al.
Publicado: (2020)

Congenital platelet disorders and health status–related quality of life
por: Blaauwgeers, Maaike W., et al.
Publicado: (2019)

Catheter Ablation for Atrial Fibrillation in Patients with Hemophilia or von Willebrand Disease
por: van der Valk, Paul R., et al.
Publicado: (2019)

Possible Targets to Reduce Fatigue in Chronic Immune Thrombocytopenia Patients – An Explorative Study
por: van Dijk, Wobke E.M., et al.
Publicado: (2022)

Desmopressin in nonsevere hemophilia A: patient perspectives on use and efficacy
por: Romano, Lorenzo G.R., et al.
Publicado: (2023)

Movement behavior in hemophilia—from medicalized training approaches toward an active lifestyle
por: Blokzijl, Johan, et al.
Publicado: (2021)

Gene Therapy for Hemophilia A: How Long Will It Last?
por: Schutgens, Roger E. G.
Publicado: (2022)

Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc
por: Traets, Marissa J.M., et al.
Publicado: (2020)

Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia
por: Versloot, Olav, et al.
Publicado: (2022)

BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2019)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Liver‐related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders
por: Isfordink, Cas J., et al.
Publicado: (2022)

Dentoalveolar Procedures in Immune Thrombocytopenia; Systematic Review and an Institutional Guideline
por: van Dijk, Wobke E. M., et al.
Publicado: (2021)

Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study
por: Schütte, Lisette M, et al.
Publicado: (2019)

Menstrual problems in chronic immune thrombocytopenia: A monthly challenge ‐ a cohort study and review
por: van Dijk, Wobke E. M., et al.
Publicado: (2022)

Gene Therapy in Hemophilia: From Hype to Hope
por: Schutgens, Roger
Publicado: (2018)

Flow cytometric mepacrine fluorescence can be used for the exclusion of platelet dense granule deficiency
por: van Asten, Ivar, et al.
Publicado: (2019)

The limitation of genetic testing in diagnosing patients suspected for congenital platelet defects
por: Blaauwgeers, Maaike W., et al.
Publicado: (2019)

New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome
por: Leebeek, Frank W. G.
Publicado: (2021)

In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients
por: Preijers, T., et al.
Publicado: (2021)

Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance
por: Schutgens, Roger E.G., et al.
Publicado: (2023)

On‐demand treatment with the iron chelator deferasirox is ineffective in preventing blood‐induced joint damage in haemophilic mice
por: Pulles, Astrid E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_thn7j5uqki9hs2qb9rn3s7fru9